Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MycarinGstudy: Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT04124965Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Oct 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04124965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124965.